2023 Form 5500 filing — Alnylam Pharmaceuticals, Inc. Savings & Investment Plan

Plain-English filing summary

According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20241010083758NAL0020698641001) for Alnylam Pharmaceuticals, Inc. Savings & Investment Plan, reported by Alnylam Pharmaceuticals, Inc. under EIN 04-3696884 and plan number 001. It reports 2,090 participants. Attached schedules in the loaded dataset include Schedule H (large plan financials), Schedule C (service provider compensation).

EFAST2 acknowledgement
20241010083758NAL0020698641001
Filing year
2023
Form type
2
Plan sponsor
Alnylam Pharmaceuticals, Inc.
EIN
04-3696884
Plan number
001
Location
Cambridge, MA
Participants
2,090
Schedules available
Schedule H, Schedule C
Received date
not reported in the loaded dataset

Reported financial snapshot (2023)

Total assets (EOY)
$275,616,093
Total liabilities (EOY)
$0
Net assets (EOY)
$275,616,093
Employer contributions
$11,168,448
Participant contributions
$27,886,695
Total income / additions
$80,849,506
Benefits paid
$15,182,936
Administrative expenses
$180,647
Total expenses
$15,401,756
Net increase / (decrease)
$65,447,750
Schedule source
Schedule H

Reported service provider compensation (Schedule C)

Compensation reported on the 2023 filing
ProviderServiceDirect comp.Indirect comp.
Merrill Lynch Pierce Fenner & SmitINVESTMENT ADVISOR$106,250not reported in the loaded dataset
Fidelity Investments InstitutionalRECORDKEEPER$43,498$0
Rsm Us LlpACCOUNTANT/AUDITOR$30,896not reported in the loaded dataset

Related Form 5500 pages